WO2008076810A2 - Azabicyclic heterocycles as cannabinoid receptor modulators - Google Patents

Azabicyclic heterocycles as cannabinoid receptor modulators Download PDF

Info

Publication number
WO2008076810A2
WO2008076810A2 PCT/US2007/087404 US2007087404W WO2008076810A2 WO 2008076810 A2 WO2008076810 A2 WO 2008076810A2 US 2007087404 W US2007087404 W US 2007087404W WO 2008076810 A2 WO2008076810 A2 WO 2008076810A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
methyl
pyridyl
ethyl
compound according
Prior art date
Application number
PCT/US2007/087404
Other languages
French (fr)
Other versions
WO2008076810A3 (en
WO2008076810A9 (en
Inventor
William R. Ewing
Yeheng Zhu
Richard B. Sulsky
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to US12/518,707 priority Critical patent/US8030306B2/en
Priority to ES07869220T priority patent/ES2384808T3/en
Priority to AT07869220T priority patent/ATE554092T1/en
Priority to JP2009541587A priority patent/JP2010513307A/en
Priority to EP07869220A priority patent/EP2094705B1/en
Publication of WO2008076810A2 publication Critical patent/WO2008076810A2/en
Publication of WO2008076810A3 publication Critical patent/WO2008076810A3/en
Priority to NO20092230A priority patent/NO20092230L/en
Publication of WO2008076810A9 publication Critical patent/WO2008076810A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)

Abstract

The present application describes CB-1 inverse agonists according to Formula (I) and (Ia), pharmaceutical compositions comprising at least one compound according to Formula (I) or (Ia), and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula (I) or (Ia), both alone and in combination with one or more additional therapeutic agents. The preferred compounds have the general Formula (Ia), including all prodrugs, pharmaceutically acceptable salts and stereoisomer, thereof, wherein R1, R2, Ar1, Ar2 are defined herein.

Claims

WHAT IS CLAIMED IS:
1. A compound according to Formula Ia:
Figure imgf000081_0001
Ia or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
Ari is aryl, which may be optionally substituted with 1-3 members selected from the group consisting of halogen, haloalkyl, cyano, alkyl, alkoxy, and haloalkoxy;
Ar2 is aryl, which may be optionally substituted with 1-3 members selected from the group consisting of halogen, haloalkyl, cyano, alkyl, alkoxy, and haloalkoxy;
Ri is alkyl, wherein the alkyl group is substituted with either an -OR4 or an -NR5R6 group;
R2 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl may each be optionally substituted with 1- 2 members selected from the group consisting of halogen, alkyl, haloalkyl, cyano, cycloalkyl, and alkoxy;
R4 is selected from the group consisting of hydrogen, alkyl, haloalkyl, and phosphates;
R5 and Re are each independently selected from the group consisting of hydrogen and alkyl, wherein the alkyl may be optionally substituted with 1-3 halogen; or
R5 and Re may be taken together with the nitrogen to which they are attached to form a heterocyclyl ring forming a 4, 5, 6, or 7 membered rings.
2. The compound according to Claim 1, wherein: Ari is phenyl optionally substituted with 1-3 members selected from the group consisting chloro, fluoro, trifluoromethyl, cyano, methyl, ethyl, methoxy, trifluoromethoxy and difluromethoxy;
Ar2 is phenyl optionally substituted with 1-3 members selected from the group consisting of chloro, fluoro, trifluoromethyl, cyano, methyl, ethyl, methoxy, trifluoromethoxy and difluromethoxy;
Ri is selected from the group consisting of methyl, ethyl and isopropyl, and is substituted with either an -OR4 or an -NR5R5 group;
R2 is selected from the group consisting of phenyl, 2-pyridyl and 3-pyridyl, each of which is optionally substituted with 1- 2 members selected from the group consisting of fluoro, chloro, methyl, ethyl, propyl, isopropyl, trifluoromethyl, difluoromethyl, cyano, cyclopropyl, cylobutyl, methoxy and ethoxy;
R4 is selected from the group consisting of hydrogen, methyl, ethyl, trifluoromethyl, difluoromethyl, -POsNa2 and -POsHNa; R5 and Re are each independently selected from the group consisting of hydrogen, methyl and ethyl, wherein the methyl and ethyl may be optionally substituted with 1 -3 halogen; or
R5 and Re may be taken together with the nitrogen to which they are attached to form a heterocyclyl ring forming a 4, 5, 6, or 7 membered rings.
3. A compound according to Claim 1 wherein:
Ri is a methyl, ethyl or isopropyl group which is substituted with an -OR4 or -NR5R6 group;
R4 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, and phosphate;
R5 and Re are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl and isopropyl; or
R5 and Re together with the nitrogen to which they are attached form a 4, 5, 6, or 7-membered ring having 1 nitrogen and the remainder of the ring members as carbon.
4. A compound according to Claim 1 wherein: R2 is selected from the group consisting of 2-pyridinyl, and 3-pyridinyl, which may be optionally substituted with 1-3 members selected from the group consisting of chloro, fluoro, methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoromethyl, cyano, and hydroxymethyl.
5. A compound according to Claim 1 wherein:
Ari is selected from the group consisting of phenyl optionally substituted with methyl, trifluoromethyl, chloro, fluoro or cyano;
Ar2 is selected from the group consisting of phenyl optionally substituted with methyl, methoxy, trifluoromethyl, chloro, fluoro or cyano;
Ri is selected from the group consisting of -CH2OR4, -CH(CH3)OR4, -C(CHs)2OR4, -CH2CH2OR4, -CH2NR5R6 , -CH(CH3)NR5R6 and -C(CHs)2NR5R6; R2 is selected from the group consisting of pheny, 2-pyridyl and 3-pyridyl, wherein the pheny, 2-pyridyl and 3-pyridyl may each be optionally substituted with 1- 2 members selected from the group consisting of fluoro, chloro, methyl, ethyl, propyl, isopropyl, trifluoromethyl, difluoromethyl, cyano, cycloproplyl, cylobutyl, methoxy and ethoxy;
R4 is selected from the group consisting of hydrogen, methyl ethyl, and -P(O)(OH)2; R5 and R6 are each independently selected from the group consisting of hydrogen and methyl.
6. A compound according to Claim 1 wherein: R2 is selected from the group consisting of: (a) phenyl substituted with cyano;
(b) pyridyl substituted with 1-2 members selected from the group consisting of methyl, ethyl, isopropyl, and trifluoromethyl.
7. A compound according to Claim 6 wherein R2 is selected from the group consisting of 4-cyanophenyl, 4-trifluoromethyl-2-pyridyl, 4-trifluoromethy-3- pyridyl, 2 -methyl-4-trifluoromethy-3 -pyridyl, 2-ethyl-4-trifluoromethy-3 -pyridyl, and 2-isopropyl-4-trifluoromethyl-3-pyridyl.
8. A compound according to Claim 1 wherein R4 is -P(O)(OH)(ONa) or -P(O)(ONa)2.
9. The compound according to Claim 1, wherein:
Ari is substituted and is selected from the group consisting of 4-chlorophenyl, 4-cyanophenyl and 4-fluorophenyl;
Ar2 is substituted and is selected from the group consisting of phenyl, A- chlorophenyl, 4-cyanophenyl, 4-fluorophenyl, 4-methylphenyl, and A- methoxyphenyl ;
Ri is selected from the group consisting of -CH2OR4, -CH(CH3)OR4, -C(CHs)2OR4, -CH2CH2OR4, -CH2NR5R6 , -CH(CH3)NR5R6 and -C(CHs)2NR5R6;
R2 is substituted and is selected from the group consisting of 4-cyanophenyl, 4-trifluoromethy-2-pyridyl, 4-trifluoromethy-3-pyridyl, 2-methyl-4-trifluoromethy-3- pyridyl, 4,4'-difluorocyclohexyl, 4-trifluoromethyl-cyclohexyl, bicyclo[2.2.1]heptyl, 3-trifluomethyl-isoxazolyl, 4-trifluoromethyl-phenyl;
R4 is selected from the group consisting of hydrogen, methyl and -P(O)(OH)2; R5 and R6 are each independently selected from the group consisting of hydrogen and methyl.
10. A pharmaceutical composition, comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier or diluent.
11. A pharmaceutical composition comprising a compound according to Claim 1 and an additional therapeutic agent.
12. A method for treating obesity comprising: administering to a patient in need of treatment a therapeutically effective amount of a compound according to Claim 1.
13. A method for effecting smoking reduction or cessation comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of Claim 1.
14. A compound according to Claim 1 selected from group consisting of:
Figure imgf000085_0001
Figure imgf000085_0002
Figure imgf000085_0003
Figure imgf000086_0001
Figure imgf000086_0002
Figure imgf000086_0003
Figure imgf000086_0004
Figure imgf000087_0001
15. A compound according to Claim 14 selected from group consisting of:
Figure imgf000087_0002
Figure imgf000087_0003
Figure imgf000087_0004
Figure imgf000088_0001
and
PCT/US2007/087404 2006-12-14 2007-12-13 Azabicyclic heterocycles as cannabinoid receptor modulators WO2008076810A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/518,707 US8030306B2 (en) 2006-12-14 2007-12-13 Azabicyclic heterocycles as cannabinoid receptor modulators
ES07869220T ES2384808T3 (en) 2006-12-14 2007-12-13 Azabicyclic heterocycles as modulators of cannabinoid receptors
AT07869220T ATE554092T1 (en) 2006-12-14 2007-12-13 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS
JP2009541587A JP2010513307A (en) 2006-12-14 2007-12-13 Azabicyclic heterocycles as cannabinoid receptor modulators
EP07869220A EP2094705B1 (en) 2006-12-14 2007-12-13 Azabicyclic heterocycles as cannabinoid receptor modulators
NO20092230A NO20092230L (en) 2006-12-14 2009-06-10 Azabicyclic heterocycles as cannabinoid receptor modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86993306P 2006-12-14 2006-12-14
US60/869,933 2006-12-14

Publications (3)

Publication Number Publication Date
WO2008076810A2 true WO2008076810A2 (en) 2008-06-26
WO2008076810A3 WO2008076810A3 (en) 2008-08-14
WO2008076810A9 WO2008076810A9 (en) 2009-07-30

Family

ID=39343511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/087404 WO2008076810A2 (en) 2006-12-14 2007-12-13 Azabicyclic heterocycles as cannabinoid receptor modulators

Country Status (8)

Country Link
US (1) US8030306B2 (en)
EP (1) EP2094705B1 (en)
JP (1) JP2010513307A (en)
CN (1) CN101631789A (en)
AT (1) ATE554092T1 (en)
ES (1) ES2384808T3 (en)
NO (1) NO20092230L (en)
WO (1) WO2008076810A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056866B2 (en) 2011-11-08 2015-06-16 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
US10183946B2 (en) 2014-11-07 2019-01-22 Hoffmann-La Roche Inc. Triazolo[4,5-D]pyrimidines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063762A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0515488A (en) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc heterocyclic derivatives and their use as therapeutic agents
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US20100216848A1 (en) * 2007-10-10 2010-08-26 Peresypkin Andrey V Liquid pharmaceutical compositions for parenteral administration of a substituted amide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063762A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A Textbook of Drug Design and Development", vol. 5, 1991, HARWOOD ACADEMIC PUBLISHERS, pages: 113 - 191
"Design of Prodntgs", 1985, ELSEVIER
"The Practice of Medicinal Chemistry", 1996, ACADEMIC PRESS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056866B2 (en) 2011-11-08 2015-06-16 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
US10183946B2 (en) 2014-11-07 2019-01-22 Hoffmann-La Roche Inc. Triazolo[4,5-D]pyrimidines

Also Published As

Publication number Publication date
ATE554092T1 (en) 2012-05-15
WO2008076810A3 (en) 2008-08-14
CN101631789A (en) 2010-01-20
US8030306B2 (en) 2011-10-04
NO20092230L (en) 2009-07-13
EP2094705B1 (en) 2012-04-18
JP2010513307A (en) 2010-04-30
EP2094705A2 (en) 2009-09-02
WO2008076810A9 (en) 2009-07-30
ES2384808T3 (en) 2012-07-12
US20100029656A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
JP6936823B2 (en) 2-Aminopyrimidine-6-one and analogs exhibiting anti-cancer and anti-proliferative activity
RU2650895C2 (en) Substituted pyrazolone compounds and methods of use
JP2019517487A5 (en)
JP2018520195A5 (en)
CA2412968A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
JP2010536887A5 (en)
JP2012511588A5 (en)
JP2017537882A5 (en)
JP2016526576A5 (en)
JP2014506599A5 (en)
EA027280B1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP2013531029A5 (en)
JP2016517417A5 (en)
RU2013149174A (en) NEW IMIDAZOOXASINE COMPOUND OR ITS SALT
JP2013544261A5 (en)
MX2021006544A (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer.
CA2684105A1 (en) Pyridine derivatives
CA2493225A1 (en) Quinoline derivatives and their use as mycobacterial inhibitors
JP2011509309A5 (en)
JP2014509600A5 (en)
JP2014502988A5 (en)
CA2720944A1 (en) Compounds and compositions as kinase inhibitors
CR20200418A (en) Arginase inhibitors and methods of use thereof
CA2539349A1 (en) 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
JP2020527173A5 (en)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780051308.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869220

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007869220

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009541587

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4525/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12518707

Country of ref document: US